Fireside Chat, Interview
Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine
- The 2030s are projected to be defined by "brain drugs," with a strategic shift from generalized obesity care to targeted treatments for cardiovascular risk, brain health, addiction, joint diseases, and cancer.
- Two Phase 3 assets may exceed Terzepatide within the GLP-1 portfolio, which includes seven other assets in clinical development, while supply constraints for injectable forms are expected to persist for a "few years" until manufacturing capacity expands from serving tens of millions to hundreds of millions.
- Manufacturing expansion requires a "10x plus" increase in capacity with a lag time of "three or four years" for new facilities, though oral solid medicines are anticipated to solve current constraints if they succeed in Phase 3.
- The timeline for drug development has been reduced from "five years" to "half that time" from idea to clinic, and from "11 years" to "half that time" from clinic to market, with a focus on breaking the R&D productivity ceiling where increased spending yields diminishing returns.
- AI is expected to deliver a "huge incumbent advantage" due to 120 years of tagged and digitized drug data, with current applications already yielding 5% to 7% manufacturing yield improvements, though most of the $5 billion invested in AI drug discovery startups is predicted "won't work."
- Human-machine collaboration is viewed as the near-term driver for useful results, with humans refining machine-generated concepts, while the first purely machine-invented drug with FDA approval is expected "quite a long time" from now.
- The company aims to achieve the equivalent of "a thousand med chemist" in the cloud via constant GPU time for in silico experimentation, with a commitment to ensure "many more good products" by 2035 by maintaining the "seed corn" of R&D investments.
- Intellectual property strategies are adapting to a US regulatory environment described as "regressing on IP" due to politics, with plans to diversify into regulatory data protection and third-country enforcement to mitigate patent losses.
- Patent concepts require re-evaluation regarding AI due to the difficulty in determining the "human inventive step," and generics are not expected to directly copy FDA files due to the cost of reproducing data.
- Gene therapies are not expected to be applicable to "common drugs" this decade but are anticipated to eventually become "one and done" treatments for serious diseases, with CRISPR investments targeting cardiovascular risk via PCSK9 protein editing to achieve 10 to 20 point LDL drops.
- Mental health and addiction are identified as the "last frontier" and harder to solve than neurodegenerative conditions, though science for conditions like Parkinson's, ALS, and Alzheimer's is now "much more tractable," with an application for Alzheimer's prevention in healthy seniors expected to be approved "later this year."
- The company intends to acquire groups via an "acqui-hire strategy" to retain talent, while acknowledging that pursuing "big ideas" involves the risk of some failures, yet maintaining that one must start with such ideas to achieve progress.
- Polygenic diseases are considered harder to solve regarding delivery compared to monogenic disorders, and the company expects the obesity management industry to expand to cover a wide range of adult diseases beyond weight loss.